Sensitivity of H5N1 Influenza Viruses to Oseltamivir: An Update

• Claas EC , OsterhausAD, van Beek R et al.: Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet351 , 472–477 (1998).
   PubMed Web of Science ®Google Scholar
• Subbarao K , KlimovA, KatzJ et al.: Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science279 , 393–396 (1998).
   PubMed Web of Science ®Google Scholar
• WHO: Evolution of H5N1 avian influenza viruses in Asia. Emerg. Infect. Dis.11 , 1515–1521 (2005).
   PubMed Web of Science ®Google Scholar
• Ong AK , HaydenFG, JohnF: Enders lecture 2006: antivirals for influenza.J. Infect. Dis.196 , 181–190 (2007).
   PubMed Web of Science ®Google Scholar
• Cheung CL , RaynerJM, SmithGJ et al.: Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis.193 , 1626–1629 (2006).
   PubMed Web of Science ®Google Scholar
• Jefferson T , DemicheliV, RivettiD, JonesM, Di PietrantonjC, RivettiA: Antivirals for influenza in healthy adults: systematic review.Lancet367 , 303–313 (2006).
   PubMed Web of Science ®Google Scholar
• Russell RJ , HaireLF, StevensDJ et al.: The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature443(7107) , 45–49 (2006).
   PubMed Web of Science ®Google Scholar
• Leneva IA , RobertsN, GovorkovaEA, GoloubevaOG, WebsterRG: The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses.Antiviral Res.48 , 101–115 (2000).
   PubMed Web of Science ®Google Scholar
• Yen HL , HerlocherLM, HoffmannE et al.: Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother.49 , 4075–4084 (2005).
   PubMed Web of Science ®Google Scholar
• Wetherall NT , TrivediT, ZellerJ et al.: Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol.41 , 742–750 (2003).
   PubMed Web of Science ®Google Scholar
• Hurt AC , SelleckP, KomadinaN, ShawR, BrownL, BarrIG: Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.Antiviral Res.73 , 228–231 (2007).
   PubMed Web of Science ®Google Scholar
• McKimm-Breschkin JL , SelleckP, UsmanT, JohnsonM: Indonesian H5N1 isolates demonstrate decreased sensivtivity to oseltamivir. Presented at: Options for the Control of Influenza VI Conference. Toronto, Canada, 17–23 June 2007 (Abstract 69).
   Google Scholar
• Rameix-Welti MA , AgouF, BuchyP et al.: Natural variation can significantly alter sensitivity to oseltamivir of Influenza A(H5N1) viruses. Antimicrob. Agents Chemother.50(11) , 3809–3815(2006).
   PubMed Web of Science ®Google Scholar
• Ives JA , CarrJA, MendelDB et al.: The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res.55 , 307–317 (2002).
   PubMed Web of Science ®Google Scholar
• Kati WM , MontgomeryD, CarrickR et al.: In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob. Agents Chemother.46 , 1014–1021 (2002).
   PubMed Web of Science ®Google Scholar
• Wang MZ , TaiCY, MendelDB: Mechanism by which mutations at His274 alter sensitivity of influenza A virus N1 neuraminidase to oseltamivir carboxylate and zanamivir.Antimicrob. Agents Chemother.46 , 3809–3816 (2002).
   PubMed Web of Science ®Google Scholar
• Matrosovich M , MatrosovichT, CarrJ, RobertsNA, KlenkHD: Overexpression of the α-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors.J. Virol.77 , 8418–8425 (2003).
   PubMed Web of Science ®Google Scholar
• Zambon M , HaydenFG: Position statement: global neuraminidase inhibitor susceptibility network.Antiviral Res.49 , 147–156 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner R , MatrosovichM, KlenkHD: Functional balance between haemagglutinin and neuraminidase in influenza virus infections.Rev. Med. Virol.12 , 159–166 (2002).
   PubMed Web of Science ®Google Scholar
• Stevens J , BlixtO, TumpeyTM, TaubenbergerJK, PaulsonJC, WilsonIA: Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus.Science312 , 404–410 (2006).
   PubMed Web of Science ®Google Scholar
• Yen HL , MontoAS, WebsterRG, GovorkovaEA: Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.J. Infect. Dis.192 , 665–672 (2005).
   PubMed Web of Science ®Google Scholar
• Govorkova EA , LenevaIA, GoloubevaOG, BushK, WebsterRG: Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.Antimicrob. Agents Chemother.45 , 2723–2732 (2001).
   PubMed Web of Science ®Google Scholar
• Govorkova EA , RehgJE, KraussS et al.: Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol.79 , 2191–2198 (2005).
   PubMed Web of Science ®Google Scholar
• Maines TR , LuXH, ErbSM et al.: Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol.79 , 11788–11800 (2005).
   PubMed Web of Science ®Google Scholar
• Zitzow LA , RoweT, MorkenT, ShiehWJ, ZakiS, KatzJM: Pathogenesis of avian influenza A (H5N1) viruses in ferrets.J. Virol.76 , 4420–4429 (2002).
   PubMed Web of Science ®Google Scholar
• Govorkova EA , IlyushinaNA, BoltzDA, DouglasA, YilmazN, WebsterRG: Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.Antimicrob. Agents Chemother.51 , 1414–1424 (2007).
   PubMed Web of Science ®Google Scholar
• Peiris JS , YuWC, LeungCW et al.: Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet363 , 617–619 (2004).
   PubMed Web of Science ®Google Scholar
• Apisarnthanarak A , KitphatiR, ThongphubethK et al.: Atypical avian influenza (H5N1). Emerg. Infect. Dis.10 , 1321–1324 (2004).
   PubMed Web of Science ®Google Scholar
• Beigel JH , FarrarJ, HanAM et al.: Avian influenza A (H5N1) infection in humans. N. Engl. J. Med.353 , 1374–1385 (2005).
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K , UiprasertkulM, PuthavathanaP et al.: A child with avian influenza A (H5N1) infection. Pediatr. Infect. Dis. J.24 , 162–166 (2005).
   PubMed Web of Science ®Google Scholar
• Chotpitayasunondh T , UngchusakK, HanshaoworakulW et al.: Human disease from influenza A (H5N1), Thailand, 2004. Emerg. Infect. Dis.11 , 201–209 (2005).
   PubMed Web of Science ®Google Scholar
• Chutinimitkul S , BhattarakosolP, SrisuratanonS et al.: H5N1 influenza A virus and infected human plasma. Emerg. Infect. Dis.12 , 1041–1043 (2006).
   PubMed Web of Science ®Google Scholar
• Ungchusak K , AuewarakulP, DowellSF et al.: Probable person-to-person transmission of avian influenza A (H5N1). N. Engl. J. Med.352 , 333–340 (2005).
   PubMed Web of Science ®Google Scholar
• de Jong MD , BachVC, PhanTQ et al.: Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N. Engl. J. Med.352 , 686–691 (2005).
   PubMed Web of Science ®Google Scholar
• de Jong MD , SimmonsCP, ThanhTT et al.: Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med.12 , 1203–1207 (2006).
   PubMed Web of Science ®Google Scholar
• de Jong MD , TranTT, TruongHK et al.: Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med.353 , 2667–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Le QM , KisoM, SomeyaK et al.: Avian flu: isolation of drug-resistant H5N1 virus. Nature437 , 1108 (2005).
   PubMed Web of Science ®Google Scholar
• Tran TH , NguyenTL, NguyenTD et al.: Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med.350 , 1179–1188 (2004).
   PubMed Web of Science ®Google Scholar
• Buchy P , MardyS, VongS et al.: Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol.39 , 164–168 (2007).
   PubMed Web of Science ®Google Scholar
• Kandun IN , WibisonoH, SedyaningsihER et al.: Three Indonesian clusters of H5N1 virus infection in 2005. N. Engl. J. Med.355 , 2186–2194 (2006).
   PubMed Web of Science ®Google Scholar
• Oner AF , BayA, ArslanS et al.: Avian influenza A (H5N1) infection in eastern Turkey in 2006. N. Engl. J. Med.355 , 2179–2185 (2006).
   PubMed Web of Science ®Google Scholar
• Gu J , XieZ, GaoZ et al.: H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet370 , 1137–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Shu Y , YuH, LiD: Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China.N. Engl. J. Med.354 , 1421–1422 (2006).
   PubMed Web of Science ®Google Scholar
• Sedyaningsih ER , IsfandariS, SetiawatyV et al.: Epidemiology of cases of H5N1 virus infection in Indonesia, July 2005–June 2006. J. Infect. Dis.196 , 522–527 (2007).
   PubMed Web of Science ®Google Scholar
• Aoki FY , MacleodMD, PaggiaroP et al.: Early administration of oral oseltamivir increases the benefits of influenza treatment. J. Antimicrob. Chemother.51 , 123–129 (2003).
   PubMed Web of Science ®Google Scholar
• Treanor JJ , HaydenFG, VroomanPS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA283 , 1016–1024 (2000).
   PubMed Web of Science ®Google Scholar
• Whitley RJ , HaydenFG, ReisingerKS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J.20 , 127–133 (2001).
   PubMed Web of Science ®Google Scholar
• Uiprasertkul M , PuthavathanaP, SangsiriwutK et al.: Influenza A H5N1 replication sites in humans. Emerg. Infect. Dis.11 , 1036–1041 (2005).
   PubMed Web of Science ®Google Scholar
• Ng WF , ToKF: Pathology of human H5N1 infection: new findings.Lancet370 , 1106–1108 (2007).
   PubMed Web of Science ®Google Scholar
• Sweeny DJ , LynchG, BidgoodAM, LewW, WangKY, CundyKC: Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat.Drug Metab. Dispos.28 , 737–741 (2000).
   PubMed Web of Science ®Google Scholar
• Ward P , SmallI, SmithJ, SuterP, DutkowskiR: Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.J. Antimicrob. Chemother.55(Suppl. 1) , I5–I21 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholson KG , AokiFY, OsterhausAD et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet355 , 1845–1850 (2000).
   PubMed Web of Science ®Google Scholar
• Kiso M , MitamuraK, Sakai-TagawaY et al.: Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet364 , 759–765 (2004).
   PubMed Web of Science ®Google Scholar
• Aoki FY , BoivinG, RobertsN: Influenza virus susceptibility and resistance to oseltamivir.Antivir. Ther.12 , 603–616 (2007).
   PubMed Web of Science ®Google Scholar
• Gubareva LV , KaiserL, MatrosovichMN, Soo-HooY, HaydenFG: Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.J. Infect. Dis.183 , 523–531 (2001).
   PubMed Web of Science ®Google Scholar
• Saad MD , BoyntonBR, EarhartKC et al.: Detection of oseltamivir resistance mutation N294S in humans with influenza A H5N1. Presented at: Options for the Control of Influenza VI Conference. Toronto, Canada, 17–23 June 2007.
   Google Scholar
• Gubareva LV , WebsterRG, HaydenFG: Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Antimicrob. Agents Chemother.45 , 3403–3408 (2001).
   PubMed Web of Science ®Google Scholar
• Fritz RS , HaydenFG, CalfeeDP et al.: Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis.180 , 586–593 (1999).
   PubMed Web of Science ®Google Scholar
• Yen HL , IlyushinaNA, SalomonR, HoffmannE, WebsterRG, GovorkovaEA: Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.J. Virol.81 , 12418–12426 (2007).
   PubMed Web of Science ®Google Scholar
• Herlocher ML , TrusconR, EliasS et al.: Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis.190 , 1627–1630 (2004).
   PubMed Web of Science ®Google Scholar
• Mishin VP , HaydenFG, GubarevaLV: Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.Antimicrob. Agents Chemother.49 , 4515–4520 (2005).
   PubMed Web of Science ®Google Scholar
• Macdonald SJ , CameronR, DemaineDA et al.: Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza. J. Med. Chem.48 , 2964–2971 (2005).
   PubMed Web of Science ®Google Scholar
• Malakhov MP , AschenbrennerLM, SmeeDF et al.: Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother.50 , 1470–1479 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi K , FurutaY, FukudaY et al.: In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem. Chemother.14 , 235–241 (2003).
   PubMedGoogle Scholar
• De Clercq E : Antiviral agents active against influenza A viruses.Nat. Rev. Drug Discov.5 , 1015–1025 (2006).
   PubMed Web of Science ®Google Scholar

Website

• WHO: Towards a unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses www.who.int/csr/disease/avian_influenza/guidelines/nomenclature/en/index.html
   Google Scholar
• Lackenby A, Hungnes O, Dudman SG et al.: Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro. Surveill. (2008) www.eurosurveillance.org/edition/v13n05/080131_2.asp
   Google Scholar